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Summary 
 
Memory is a polygenic trait that enables humans to 
learn and remember information. A novel genome-wide 
association study performed in 2006 implicated that a 
polymorphism in the KIBRA gene was associated with 
enhanced episodic memory. Very little detail is known 
about the pathways to which this gene contributes; 
however, research implicates that the cytoplasmic 
protein plays a structural role in neurons. Recent 
studies examining the gene’s association with memory 
performance are consistent and age-independent in 
healthy individuals; however, conflicting results when 
examining subjects with impaired memory suggest 
KIBRA’s effects are complex. Although one memory-
enhancing therapy has suggested based upon these 
findings, future research must focus on the genetic and 
molecular mechanisms through which KIBRA acts. 
Greater understanding of these pathways will allow for 
the discovery and understanding of therapies that can 
potentially treat non-disabling memory declines 
associated with healthy aging, as well as impaired 
memory associated with diseases such as Alzheimer’s. 
 
Introduction 
 
Memory is a fundamental cognitive ability that enables 
humans to learn and remember information. This polygenic 
trait gives meaning to people’s lives by providing context and 
understanding to daily events. Episodic memory, which 
refers to the encoding and retrieval of facts that occur at a 
specific time, is thought to have a heritability of 
approximately 50 percent (McClearn et al., 1997). 
Ascertaining the genetic aspects of this ability could provide 
promising targets for memory-enhancing pharmaceuticals. 
These drugs could play a role in the treatment of non-
disabling memory declines associated with healthy aging. 
Furthermore, these medications could act as potential 
treatments for patients with impaired memory, such as those 
with Alzheimer’s disease, other dementias, or mild cognitive 
impairment. The genetic information behind memory could 
theoretically be used to improve the lives of  approximately 
5.2 million people in the United States living with Alzheimer’s 
disease (www.alz.org).  
Recent technological advances have altered 
geneticists’ inquiry of memory, for whole-genome 
association studies allow for the identification of specific 
points of variation in human DNA that underlie particular 
diseases or traits (www.genome.gov). Identifying the genetic 
factors that influence memory is central to discovering and 
developing medicines that target diseases with increased 
precision and reduced risks. One such novel study carried 
out in 2006 reported an association between a 
polymorphism in the KIBRA gene and episodic memory. 
Before this discovery is illuminated, however, one must first 
examine the scientific history of the gene itself. 
________________________________________________  
 
*This author wrote the paper for Biology 352: Molecular Genetics taught by Dr. 
Karen Kirk. 
 
 
Discovering and Characterizing KIBRA 
In 1998, Nagase et al. reported the sequences of 100 cDNA 
clones from a set of size-fractionated human brain cDNA 
libraries. The scientists of the Kazusa DNA Research 
Institute focused their sequencing efforts on the analysis of 
large cDNAs, which they defined as over 4 kb. Clones were 
then selected for sequencing if the protein product was also 
large (over 50 kDa). One of the 100 sequences described 
was KIAA0869, which was further classified as 3,408bp long 
with an open reading frame (ORF) length of 888 amino acid 
residues. The gene was found to be located on chromosome 
5 using the UniGene database. Furthermore, using RT-PCR 
ELISA, the scientists found KIAA0869 was highly expressed 
in the liver and kidney, while intermediate expression was 
detected in the brain, lung, pancreas, and ovary. Weak 
expression was observed in the heart and testis, and no 
expression was found in skeletal muscle and spleen 
(Nagase et al, 1998).  
 Almost five years later, the actual structure of 
KIAA0869 was elucidated. Kremerskothen et al. further 
characterized the gene in 2003, providing its current names 
based upon their findings: WW, C2, and Coiled-Coil 
Containing 1 (WWC1), also known as Kidney and Brain 
Expressed Protein (KIBRA). The gene is more commonly 
referred to by the latter term KIBRA. Using a yeast two 
hybrid screen with the human Dendrin protein as bait, 
Kremerskothen et al. (2003) isolated what they at first 
entitled K7 due to its strong activation of reporter genes. 
They found that K7 contained a cDNA of approximately 
4.1kB with an ORF encoding a 1113 amino acid protein. 
Furthermore, Kremerskothen et al. (2003) identified that the 
sequence of K7 starting at amino acid 224 was identical to 
the KIAA0869 sequence described by Nagase et al. (1998). 
Through hybridization of cDNA to genomic fragment, the 
gene was mapped to chromosome 5q34-5q35.2 (OMIM, 
Kremerskothen et al. 2003).   
 Once Kremerskothen et al. (2003) identified the 
protein, they set forward to further characterize the structure; 
a representation is shown below in Figure 1. These 
researchers correctly hypothesized that the hydrophilic 
protein was cytoplasmic, for it contained neither signal 
sequences nor hydrophobic stretches to implicate a role in 
membrane signaling. Two amino-terminal WW domains, the 
smallest globular domain known to mediate protein-protein 
interactions by binding to proline-rich sequences, were 
identified; by using mutated fusion proteins in a phage 
ELISA, the interaction between the WW domains and target 
proteins was found to be predominantly mediated by the first 
WW domain. The binding specificity of the second WW 
domain remains unknown (Kremerskothen et al., 2003). The 
researchers also identified a C-terminal glutamic acid-rich 
stretch as well as a C2-like domain, implying that K7 is a 
Ca2+-binding protein (Kremerskothen et al., 2003). A 
Northern blot was performed to examine the expression of 
K7. Because the 4.3kB transcript was highest in kidney and 
brain, Kremerskothen et al. (2003) called the transcript 
KIBRA. The cellular distribution of the transcript within the 
cytoplasm was later confirmed by analyzing green monkey 
kidney cells transfected with plasmids that encoded Myc-
tagged KIBRA. Kremerskothen et al. (2003) also determined 
that mutants lacking the WW domains were still expressed 
only in the cytoplasm. Because there was no difference in 
the distribution of full-length and truncated KIBRA, the WW 
domains (or the interactions they direct) are not necessary 
for correct localization. 
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Figure 1. A schematic representation of the KIBRA protein adapted from Traer et al. (2007). 
 
 
The Function of KIBRA 
Little is known about the specific function of KIBRA aside 
from which proteins it interacts with. Kremerskothen et al. 
(2003) postulated that the protein plays a structural role in 
the cell. This hypothesis is supported by KIBRA’s interaction 
with Dendrin, a protein associated with the cytoskeleton. 
Similar to this study, much of the other known information 
about the functional properties of KIBRA has been 
uncovered while studying other proteins.  For example, one 
research group set out to determine the function of 
KIAA0513 and the gene’s relationship to schizophrenia 
(Lauriat et al., 2006). Using a two-hybrid screen, KIBRA was 
found to interact with the protein product of this gene, which 
is suspected to be involved in signaling pathways related to 
neuroplasticity. Similarly, KIBRA was found to complex with 
dynein light chain 1 (DLC1) when researchers set out to 
identify DLC1’s pathway. This association seems essential 
for estrogen receptor-α transactivation in breast cancer cells 
and is thought to play a mechanistic role in conferring an 
optimal ER transactivation function as well as the 
proliferation of these cells (Rayala et al., 2006).  This 
hypothesis, however, has not yet been confirmed. 
 Another binding partner of KIBRA, protein kinase 
C ζ (PKC-ζ), was identified by Buther, Plaas, Barnekow, and 
Kremerskothen in 2004. This protein plays a significant role 
in signal transduction processes, including the formation of 
memory. The study suggests that PKCζ phosphorylation 
may regulate the cellular function of KIBRA by 
phosphorylating the WW domain at the C-terminus (Buther, 
Plaas, Barnekow, & Kremerskothen, 2004). Although these 
binding partners of KIBRA have been identified, the specific 
functions of the gene in the pathways are not yet 
understood. 
 
KIBRA and Memory 
Aside from the basic structure and associated proteins, 
however, KIBRA was not well studied until a press release in 
2006; the Translational Genomics Research Institute (TGen) 
announced the discovery of a gene that “plays a significant 
role in memory performance in humans” (TGen, 2006). The 
study was the first to describe scanning the human genetic 
blueprint to identify cognitive differences between humans; 
Passotiropoulos et al. (2006) stated that a genome-wide 
screen with over 500,000 SNPs using microarrays showed 
that a single nucleotide polymorphism (SNP) within the ninth 
intron of the KIBRA gene was significantly associated with 
memory performance in three independent subject groups. 
An initial screen of 341 young adults in Switzerland were 
separated into four groups based upon their verbal memory 
performance and were consequently genotyped for 502,627 
SNPs. Subjects with the SNP rs1707145 T allele of KIBRA 
had 24% better recall five minutes after word presentation 
and 19% better recall 24 hours later than non-carriers. To 
verify these results, similar tests were performed on a 
second, median-aged cohort in the United States, as well as 
a third population of young adults from Switzerland 
(Passotiropoulos et al., 2006). Subjects heterozygous or 
homozygous for the T allele had better memory performance 
than non-carriers (CC allele). 
 While Passotiropoulos et al. (2006) demonstrated 
the association of the rs1707145 T allele with better episodic 
memory in young and middle aged adults, a study performed 
in 2008 used healthy elderly subjects to replicate the findings 
(Schaper, Kolsch, Popp, Wagner, and Jesseen, 2008). This 
study ensured that age did not affect the role the SNP allele 
had on recall performance.  
 Furthermore, Passotiropoulos et al. (2006) 
showed that KIBRA was expressed in memory-related brain 
structures (such as the hippocampus), and fMRI studies of 
the three cohorts detected allele-dependent differences in 
hippocampal activations during memory retrieval, supporting 
KIBRA’s connection to memory. Johannsen, Duning, 
Pavenstadt, Kremerskothen, and Boeckers (2008) similarly 
found that KIBRA was expressed in the hippocampus, 
cortex, hypothalamus, and cerebellum. They propose that 
KIBRA has a diverse role in memory-related and 
neuroendocrine mechanisms, including brain development 
and memory formation by acting as a postsynaptic scaffold 
protein connecting cytoskeletal and signaling proteins.  
 Almeida et al. (2008) also ensured that the 
polymorphism’s association with memory performance, 
especially in the elderly, was related to episodic memory and 
not the decreased expression of the mild cognitive 
impairment (MCI) phenotype. Those with MCI, a trait defined 
as an increased risk of developing dementia as one ages, 
often show normal age-adjusted cognitive abilities but 
display significant deficits in tests of episodic memory. 
Because the genetic determinants of MCI and dementia may 
not be identical, the authors suspected that the KIBRA 
polymorphism could play a role in the development of MCI 
later in life. This hypothesis, however, was unsupported; 
although the results replicated those of Passotiropoulos et 
al. (2006) and Almeida et al. (2008) regarding episodic 
memory enhancement, no statistically significant evidence 
was found suggesting CC carriers were at higher risk for 
MCI (although a slight trend in this direction was observed). 
 
KIRBA and Memory Disorders 
Since the T allele of the KIBRA gene is associated with 
improved episodic memory in all ages, Rodriguez-Rodriguez 
et al. (2009) set out to determine if the polymorphism 
conferred protection to Alzheimer’s disease (AD). AD is 
known to not only impair episodic memory but adversely 
affects hippocampal function, a structure that shows high 
expression of KIBRA. The study examined 391 subjects who 
met criteria for probable sporadic AD, but the results were 
inconsistent with an association of allelic differences 
between the AD subjects and controls. However, when the 
 
 
	  
AD subjects were stratified by age of onset, a significant 
correlation was found for the T allele of rs17070145 and 
increased susceptibility of AD in the very elderly (classified 
as over 86 years of age). This result conflicts with previous 
memory studies in healthy individuals that showed age-
independent effects of KIBRA alleles (Passotiropoulos et al., 
2006; Schaper, Kolsch, Popp, Wagner, and Jesseen, 2008). 
Rodriguez-Rodriguez et al. (2009) propose that different 
genetic backgrounds of late- and early-onset patients may 
enhance the effect of the KIBRA gene, leading to a greater 
susceptibility for late expression of the disease. 
 These findings also contradict a study in which 
non-carriers of the T allele have a moderate but significantly 
increased risk of AD; Corneveaux et al. (2008) suggest that 
the T allele may have a protective effect with progression 
increasing later age-of-onset. These opposing results may 
be due to differences in power, for the study performed by 
Corneveaux et al. (2008) used 2.5 times the number of 
subjects, including relatively error-free postmortem tissue. 
Unlike this sample, Rodriguez-Rodriguez et al. (2009) used 
subjects from an isolated region in Spain.  
 Corneveaux et al. (2008) also utilized microarray 
to examine differences in expression levels of KIBRA and 
four known binding partners, hypothesizing that the KIBRA 
pathway would exhibit deregulation in the brains of AD 
patients. Compared to controls, KIBRA was over-expressed 
while three of the four binding partners were under-
expressed in three areas of the brain known to be affected 
by AD. Furthermore, PET scans suggested an association 
between noncarriers of the T allele and glucose metabolism 
in certain brain regions known to be metabolically affected 
by AD (Corneveaux et al., 2008).  
 Due to the opposing effects of rs17070145 alleles 
on episodic memory and AD, Nacmias et al. (2008) chose to 
examine the relationship between the KIBRA SNP and 
subject memory complaints (SMC), or problems with 
everyday memory. Their study aimed to identify an 
association between SMC, which are common in older 
adults, while taking into account the ApoE genotype as it has 
a selective effect on episodic memory, attentional functions, 
and hippocampal volumes in both healthy and AD subjects 
(Hashimoto, 2001).  SMC subjects with the CT/TT genotype 
did not perform as well as those with the CC genotype on 
long-term memory tests. Although a small sample size may 
have contributed to differences in results from this study and 
its predecessors, Nacmias et al. (2008) advocate that this 
contradicting data suggests KIBRA’s role is quite complex; 
the KIBRA genotype may affect memory performance 
differently in healthy subjects compared to those with 
memory deficits (AD or SMC). This hypothesis supports the 
unexpected results of Rodriguez-Rodriguez et al. (2009), for 
the SNP was associated only in very elderly AD patients; 
however, studies of healthy subjects found that the 
association was age-independent (Passotiropoulos et al., 
2006; Almeida et al., 2008). 
 
From Polymorhpism to Pharmaceuticals 
The rs1707145 SNP in KIBRA has shown conflicting effects 
on memory. Although Nacmias et al. (2008) believes the 
polymorphism has varying effects depending upon the health 
of the individual, Huentelman et al. (2009) imply that prior 
results raise the possibility that a common molecular 
mechanism may contribute to both episodic memory and the 
pathological and clinical features of AD. The hypothesis of 
overlapping mechanisms drove these scientists to attempt to 
target specific processes for memory-enhancing and AD 
risk-reducing therapies. Based upon the previously 
mentioned findings and a pathway analysis approach, 
Huentelman et al. (2009) hypothesized a pathway that could 
be used to alter KIBRA activity. The RhoA/ROCK/Rac 
pathway was demonstrated to be upstream of  PKC-ζ, one of 
KIBRA’s binding partners. Furthermore, this pathway has 
been implicated in key neurobiological functions such as 
neurite outgrowth and other processes that underlie 
cognitive function. Based upon this knowledge, Huentelman 
et al. (2009) inhibited the RhoA/ROCK/Rac pathway in a 
rodent model using hydroxyfasudil to determine if enhanced 
memory and learning would ensue. Both spatial learning and 
working memory were improved in aged rats, implicating 
ROCK activity in these processes. Huentelman et al. (2009) 
state that one plausible mechanism may be phosphorylation 
of KIBRA by PKC-ζ after activation of Rac-1. However, this 
hypothesis must be confirmed by further experimentation. If 
substantiated, this drug may have clinical relevance as a 
cognitive enhancer, for the parent drug (Fasudil) is safe and 
well-tolerated by humans – it is currently used to treat stroke 
victims. More research must be done, however, in order to 
determine if only KIBRA is altered and not the molecules it 
interacts with. 
 
Conclusion 
 
The findings of Huentelman et al. (2009) support the quest 
for pharmaceuticals that could potentially treat cognitive 
impairment, cushion the impact of aging on memory, or even 
enhance learning and memory. KIBRA is associated with 
many other proteins in significant processes, such as 
episodic memory and late-onset Alzheimer’s disease. 
However, the precise mechanisms through which KIBRA 
contributes to these pathways are not fully understood or 
confirmed; conflicting results must be resolved by further 
research. Overall, these results suggest that KIBRA’s role in 
both episodic memory and AD is complex. Further 
examination of these mechanisms must occur, as this 
knowledge could allow for the discovery and understanding 
of therapies such as hydroxyfasudil. The findings of 
Huentelman et al. (2009) support the quest for 
pharmaceuticals that could potentially treat cognitive 
impairment, cushion the impact of aging on memory, or even 
enhance learning and memory. However, even this drug, 
although successful in improving memory in rats, is not yet 
understood.   
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